AUTHOR INDEX

Ailhaud, G. 145
Alaupovic, P. 105, 151, 181, 275
Attman, P. -O. 275
Ayrault-Jarrier, M. 151

Bard, J. M. 267
Bekaert, E. D. 151
Bojanovski, D. 295
Bojanovski, M. 295
Borén, J. 205
Brewer, H. B. Jr 139
Brindley, D. N. 349
Burdelski, M. 295

Camato, R. N. 259

Dahlén, G. H. 189
Dashti, N. 219
Delcroix, C. 171
Delplanque, B. 159

Fruchart, J. -C. 145
Fugate, R. D. 237

Graham, L. 205

Hayashi, A. 301

Innis, S. M. 39

Jacotot, B. 159

Kelley, J. L. 231
Knight-Gibson, C. 151, 181
Kolesnick, R. N. 1
Koren, E. 237
Koscec, M. 237

Lee, A. G. 323
Lee, D. M. 245
Lontie, J. -F. 171
Lükermann, R. 295

Maeda, H. 281
Malmendier, C. L. 171
Marcel, Y. L. 259
Matsubara, T. 301
McConathy, W. J. 195, 237
Mercuri, O. 181
Milne, R. W. 259
Miyabo, S. 281

Nakai, T. 281

Oida, K. 281
Olofsson, S. -O. 205

Provost, P. 259

Rader, D. J. 139
Rassart, E. 259
Richard, J. L. 159

Salter, A. M. 349
Schinella, G. 181
Schulz-Falten, J. 295
Scott, J. 205
Sturm, E. 295

Takahashi, S. 281
Takau, H. 281
Tamai, T. 281
Tavella, M. 181
Tournier, H. 181
Tremblay, N. M. 259
Trieu, V. N. 195

Wang, C. -S. 253
Weech, P. K. 259
Wettesten, M. 205
White, A. 205

SUBJECT INDEX

Acyl-CoA:sphingosine *N*-acyltransferase 14
Ca^{2+}, Mg^{2+}-Adenosine triphosphatase, reconstituted with phosphatidylcholines 336, 340, 343
Na^{+}, K^{+}-Adenosine triphosphatase, cholesterol effects 339
Adipose tissue, *n*-6 and *n*-3 fatty acids during development 58
Adrenaline
  LDL receptor in liver 354
  VLDL secretion 358
Alagille syndrome 296–300
Alcohol, atherosclerosis and ApoA 149
Aminoalkylphosphonic acids, FAB/MS 320
Anaesthetics, essential fatty acids and tolerance to 79
Apolipoproteins
  chemical classification 112
  cholestasis 295–300
  diabetes 281–294
  dyslipoproteinemias and atherosclerosis 125
  fractionation and characterization of lipoprotein families 116
  hormonal regulation 355
  isolation and characterisation 107
  kinetics 142
  markers of lipoprotein particles 112
  metabolic and functional properties of lipoprotein families 122
Apolipoprotein(a)
  atherosclerosis-thrombosis 192
  ligand binding 196
  structure 189, 195
Apolipoprotein A
cardiovascular disease 140
  cholestasis 299
  dietary fat 163
  dyslipoproteinemias 126
  fractionation of lipoprotein families 116, 118
  HDL metabolism 141
  hereditary systemic amyloidosis 142
  isolation and characterization 107
  metabolic and functional properties of lipoprotein families 122
Apolipoprotein A-containing lipoprotein particles 268
  clinical significance 147, 270
  concanavalin A affinity chromatography 183
  isolation and composition 146
  measurement 269
  pharmacological modulation 271
  physiological role 146
  production by Caco-2 cells 227
  production by HepG2 cells 225
  quantitative determination 147
Apolipoprotein A-I deficiency, LP-A-II in 154
Apolipoprotein A-I-lipoprotein particles, effect of diet 159
Apolipoprotein B
  atherosclerosis 129
  dietary fat and secretion of 163, 221
  dyslipoproteinemias 127
  fractionation of lipoprotein families 116, 119
  isolation and characterization 107
  metabolic and functional properties of lipoprotein familes 122
  production by HepG2 cells 222
  structure 205
  thiolester linkages in 245–252
Apolipoprotein B-containing lipoproteins 268
  clinical interest 270
  concanavalin A affinity chromatography 183
  lipoprotein(a) interactions 196
  measurement 269
  pharmacological modulation 271
  placenta 65
  production by Caco-2 cells 227
  production by HepG2 cells 224
  renal insufficiency 277
Apolipoprotein B-48 283, 287
  diabetes 288
Apolipoprotein B-100 287
  biosynthesis 211
  intracellular transport 212
  secretion 212
Apolipoprotein B-100 containing lipoproteins
  assembly 211, 214
  fate of 207
  secretion 212
  secretory pathway 207, 210
Apolipoprotein C
  isolation and characterization 107
  in plasma 183
Apolipoprotein C-II
  functional domains 255
  gene mutation 257
  lipoprotein lipase interaction 256
  structure 253
Apolipoprotein D 109, 259
  animal studies 262
  clinical studies 265
  immunochemistry 261
  sites of gene expression 263
  structure and properties 260
Apolipoprotein E 109
  diabetes 285
  macrophages 239
  plasma 183
Apolipoprotein F 109
Apolipoprotein G 109
Apolipoprotein H 110
Apolipoprotein J 110
Atherosclerosis
  alcohol and ApoA 149
  diabetes 282, 286, 353, 356
  hormonal regulation 356, 358
  lipoprotein(a) 191
  lipoprotein A-I and B 270
  lipoprotein families 128
  role of macrophages in regression 237–243
  sphingomyelin 7, 8

Bacteriorhodopsin 331
Biliary atresia 295–300

Blood–brain barrier, *n*-6 and *n*-3 fatty acids 59
Breast gross cystic disease, ApoD 260, 265
Byler's disease 295–300

Cardiovascular disease
  ApoA-containing lipoprotein particles 147
  diabetes 282, 286
  dietary fatty acids 159
  HDL 139
  lipoprotein(a) 189–194, 195–203
  lipoprotein families 128, 270
Catecholamines
  LDL receptor in liver 354
  VLDL secretion 358
Ceramidases 15
Ceramide aminoethylphosphonate, FAB/MS 309
Ceramide kinase 24
Ceramide 1-phosphate 5, 24
Ceramides
  degradation 15
  FAB/MS 316
  measurement 5
  signal transduction 27
  synthesis 14
  tissue distribution 7
Ceramidosis 15
Cholestasis 295–300
Cholesterol
  ApoA interaction 146
  degradation in macrophages 239
  diabetes 287
  dietary, regulation of lipoprotein synthesis and secretion 221
  lipoproteins and metabolism 123
  lipoprotein production by HepG2 cells 223
  low density lipoprotein receptor expression 359
  membrane protein interaction 339
  sphingomyelin interaction 7
Cholestyramine 271
Chylomicrons
  apolipoproteins in 113
  diabetes 283, 286
  VLDL secretion 357
CNS development, essential fatty acids 50, 52
Colestipol 272
Collisionary activated dissociation mass spectrometry 303
Colonic carcinoma cells, lipoprotein production 226
Concanavalin A affinity chromatography, lipoproteins 117, 181–187, 225
Cyclohexanedione, modified LDL 174

Desaturase
  in developing tissues 52, 61
  essential fatty acid metabolism 45
Development
  adipose tissue, essential fatty acids 58
  CNS, essential fatty acids 50, 52, 67
  desaturation of *n*-6 and *n*-3 fatty acids 61
  fatty acid uptake by brain 58
  liver, essential fatty acids 56
  placental transfer of *n*-6 and *n*-3 fatty acids 63
Diacylglycerol kinase 24, 27
1, 2-Diacylglycerols, sphingomyelin degradation 20
Diabetes
  apolipoprotein abnormalities 285
  cardiovascular disease 282, 353, 356
  exogenous lipoproteins and atherogenesis 286
  lipoprotein abnormalities 283
Dietary fat
  effect on LP-A particles 148, 159
  regulation of lipoprotein synthesis and secretion 220
Dietary fatty acids 41, 74, 81, 160
N, *N*-Dimethylsphingosine 29
Diphenylhexatriene 329
Dyslipoproteinemia
  HDL metabolism 141
  lipoprotein families 125
  renal insufficiency 276, 278

ELISA, LP-A 269
Endoplasmic reticulum, ApoB-100 207
Endothelial cells, *n*-6 and *n*-3 fatty acids 60
Epidermal growth factor, effect of sphingoid bases 27
Essential fatty acids 39–103
  clinical studies 81
  CNS 50, 67
  deficiency 41, 68
  desaturation in developing tissues 61
  development 50, 52, 56, 67, 90
  diet 41, 74, 81
  growth 90
  infant formulas 66
  marine oils 75
  membranes 92
  metabolism 45, 58
  milk 65, 90
  nomenclature 41
  placental transfer 63
  premature infants 81
  recovery from deficiency 73
  uptake by brain 58
Estrogens, LDL receptor expression 351, 355
Ethanol, essential fatty acids and tolerance to 79
Ethanolamine phosphoglycerides
  in blood, effect of dietary fat 82
  in retina 51

Farber's Lipogranulomatosis 15
Fast atom bombardment mass spectrometry 302
  aminoalkylphosphonic acids 320
  ceramides 316
  fatty acids 317
  gangliosides 315
  glycerophospholipids 305
  glycoglycerolipids 312
  glycosphingolipids 313
  long chain bases 318
  phosphosphingolipids 309
  sugars 318
  sulfoglycolipids 315
Fatty acids
  developing brain 52
  dietary, effect on ApoA-I particles in plasma 160
  effect on lipoprotein production by HepG2 cells 222
  essential, growth and development 39–103
  FAB/MS 317
  in LP-A and LP-B in plasma 185
  thiolester-linked in ApoB 249
Fenofibrate 271, 272
α Fetoprotein 60
Fish oil 48, 75, 89

Gangliosides
FAB/MS 315
in CNS, essential fatty acid deficiency 69
GCDFP-24 260
Glomerulosclerosis 278
Glucagon
LDL receptor in liver 354
VLDL secretion 358
Glucocorticoids
LDL receptor in liver 353
VLDL secretion 356
Glycerophospholipids
blood, effect of dietary fat 81, 91
developing brain 53
developing liver 56
essential fatty acids in 46, 47, 51
FAB/MS 305
milk 65
Glycolipids, FAB/MS 312
Glycosylated LDL 175
Growth, dietary essentiality of *n*-6 and *n*-3 fatty acids 41

Hemodialysis, lipoproteins 276, 277
HepG2 cells, lipoprotein production by 125, 222–226
Hereditary systemic amyloidosis 142
High density lipoprotein
apoprotein A 146
apoprotein A-II 151
apoproteins in 113, 140
cardiovascular disease 131, 139, 147, 155
diabetes 285
dietary fat 160
hepatic and intestinal secretion 220
metabolism 141
renal insufficiency 275
Tangier disease 141
HMG CoA reductase inhibitors 272
Hypercholesterolemia, lipoproteins 128, 183, 271
Hypertriglyceridemia, lipoproteins 128, 183

Infant formulas
fish oil 77
glycerophospholipids in blood 82
n-6 and *n*-3 fatty acids in 40, 66
Insulin
LDL receptor in liver 353
lipoprotein production by HepG2 cells 223
VLDL secretion 356
Intermediate density lipoproteins 284, 349, 355
Intestine, lipoprotein secretion 220

KDEL type protein 213
3-Ketosphinganine 17, 18
Kidney, lipoprotein abnormalities in renal insufficiency 275–279

Learning behaviour, essential fatty acids 79
Lecithin:cholesterol acyl transferase, ApoD association 261
Lignoceryl-CoA:sphingosine *N*-acyltransferase 14, 15
Lipid nutrition 41, 74, 81
Lipoproteins
abnormalities in diabetic patients 283
apolipoprotein composition and classification 105–138
hepatic and intestinal secretion 220
hormonal regulation 355
nutritional regulation of synthesis and secretion 220
sphingomyelin in 7
Lipoprotein(a)
atherosclerosis and thrombosis 189–194
interactions 195–203
Lipoprotein A containing particles 268
clinical interest 270
concanavalin A affinity chromatography 181–187
measurement 269
pharmacological modulation 271
production by Caco-2 cells 227
production by HepG2 cells 225
Lipoprotein A-I containing particles, effect of dietary fat 159
Lipoprotein A-II containing particles
characterization and isolation 152
putative role 155
Lipoprotein B containing particles
Caco-2 cells 227
clinical interest 270
concanavalin A affinity chromatography 181–187
HepG2 cells 224
in vivo kinetics 177
measurement 269
pharmacological modulation 271
renal insufficiency 277
thiolester bonds 246
Lipoprotein lipase
ApoC-II interaction 256
diabetes 283
renal insufficiency 277
Lipoprotein receptors, diabetes 286
Lipoprotein-X, cholestasis 296
Liver
desaturases during development 61
LDL receptor, hormonal regulation 350
lipoprotein secretion 220
n-6 and *n*-3 fatty acids during development 56
Long chain bases, FAB/MS 318
Long chain polyenoic fatty acids 39, 40
clinical studies 81
CNS during development 50, 52
liver during development 56
metabolism 45
milk 65
origin in developing tissues 58
placental transfer 63
Longevity, ApoA particles 148
Low density lipoproteins
apoproteins in 113
diabetes 284, 286
hormones and catabolism 349–360
in vivo kinetics 172–180
lipoprotein(a) binding 196
macrophage scavenger receptors 231
plasminogen binding 198
receptor binding 174
Low density lipoprotein receptor 350
estrogens 351
glucagon and catecholamines 354
insulin and glucocorticoids 353
thyroid status 352
VLDL secretion 355

Lysosphingolipids, protein kinase C inactivation 21

Macrophages
degradation of cholesterol crystals 239
regression of atherosclerosis 237–243
Macrophage scavenger receptors 231
purification and structure 232
regulation 233
Malondialdehyde, modified LDL 175, 232
Marine oils 75
Mass spectrometry/fast atom bombardment 301–322
Maternal diet
n-6 and *n*-3 fatty acids in fetus 63
n-6 and *n*-3 fatty acids in milk 66
Membrane fluidity
essential fatty acids 79
phosphatidylcholine/sphingomyelin ratio 4
phospholipid bilayers 328
proteins 335
viscosity 323
Membrane proteins, lipid effects 323–348
Metarhodopsin 343
Milk, *n*-6 and *n*-3 fatty acids in 40, 65, 90
Monoclonal antibodies, ApoD 261
Monocyte-specific colony stimulating factor 233
Monounsaturated fatty acids, effect on apolipoproteins in plasma 163
Motor skills, *n*-6 and *n*-3 fatty acids 78
Myelin
essential fatty acid deficiency 69
essential fatty acids in 52, 55
Myocardial infarction, lipoprotein(a) 191

Niacin 272
Niemann-Pick disease 8, 11
Noninsulin-dependent diabetes mellitus, ApoB-48 metabolism 281–294

Oleate
effect on lipoprotein production in Caco-2 cells 226
effect on lipoprotein production in HepG2 cells 222

Palmitoylated proteins 248
Parenteral nutrition, essential fatty acids 43
Phorbol esters, protein kinase C activation 20
Phosphatidylcholine
Ca^{2+}, Mg^{2+}-ATPase binding 336, 340, 343
FAB/MS 306
physical properties 3
Phosphatidylcholine:ceramide cholinephosphotransferase, sphingomyelin synthesis 10
Phospholipid bilayers, motion 328
Phospholipids, FAB/MS 305
Phosphosphingolipids, FAB/MS 309
Phytosphingosine 19
Placenta, transfer of *n*-6 and *n*-3 fatty acids 63
Plasminogen, binding to LDL_2 198
Privastatin 271
Premature infants, essential fatty acids 85
Proline, inhibition of LDL_2 binding to Apo(a) 198
Protein acylation 248
Protein disulfide isomerase 207, 213
Protein kinase C, effect of sphingoid bases 20
Protein motion 332
Psychosine 318

Renal insufficiency, lipoprotein abnormalities 275–279
Retina, essential fatty acids 51, 79
Retinal rod outer segment disc membrane 343
Reverse cholesterol transport 155
Rhodopsin 343

Salvage compartment 213
Saponins, sphingomyelin degradation 13
Scavenger receptor 231–235
diabetes 286
Secondary ion mass spectrometry 302, 303
Secretory proteins 206
Serine palmitoyltransferase 17
Serine phosphoglycerides, in retina 51
Signal recognition particle 206
Signal transduction, sphingomyelin and derivatives 20
Simvastatin 271
Sphinganine 18
Sphinganine kinase 19
Sphinganine 1-phosphate aldolase 19
Sphingenine, FAB/MS 318
Sphingoethanolamine, FAB/MS 308, 309
Sphingoid bases
degradation 19
measurement 5
protein kinase C inhibition 20
synthesis 17
tissue distribution 7
Sphingomyelin 1–38
cellular and tissue distribution 6
cholesterol metabolism 7
degradation 11, 20
FAB/MS 309
measurement 5
physical properties 2
relationship with phosphatidylcholine 4
signal transduction 20
structure and composition 2
synthesis 9, 30
Sphingomyelinase 22
Sphingosine
effect on protein kinase C 20
induced calcium release 31
measurement 6
Stress, VLDL production 357
Sugars, FAB/MS 318
Sulfoglycolipids, FAB/MS 315

Tangier disease 120, 124
HDL metabolism 141
Tetramethylammonium-diphenylhexatriene 331
Thiolester bonds, ApoB 245
Thrombosis, lipoprotein(a) 192
Thyroid status, LDL receptor in liver 352, 355
Triglyceride-rich lipoproteins 124
coronary artery disease 129, 130
diabetes 283, 288
renal insufficiency 275, 277
Triglycerides, lipoprotein(a) relationship 200

Uremic dyslipoproteinemia 278

Vegetarian nutrition, lipids in breast milk 82, 91
Very high density lipoprotein
  apoproteins in 113
  hepatic and intestinal secretion 220
Very low density lipoprotein
  apoproteins in 113
  diabetes 283
  renal insufficiency 276
  secretion and LDL catabolism 355
  Tangier disease 124
Viscosity, membrane fluidity 323
Visual function, *n*-6 and *n*-3 fatty acids 78, 80, 92
Vitamin D3, induced phospholipid changes 25

Weaning foods, *n*-6 and *n*-3 fatty acids in 67